Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged. The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Alere ( ALR), down 13.5%, Catamaran ( CTRX), down 3.1%, Taro Pharmaceutical Industries ( TARO), down 2.7%, ResMed ( RMD), down 1.9% and Teva Pharmaceutical Industries ( TEVA), down 1.7%. Top gainers within the sector include Amgen ( AMGN), up 1.1%, AstraZeneca ( AZN), up 1.0%, Gilead ( GILD), up 0.9%, Medtronic ( MDT), up 0.9% and Eli Lilly and ( LLY), up 0.8%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Endo International ( ENDP) is one of the companies pushing the Health Care sector lower today. As of noon trading, Endo International is down $1.60 (-2.4%) to $66.02 on light volume. Thus far, 632,690 shares of Endo International exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $65.94-$68.10 after having opened the day at $67.73 as compared to the previous trading day's close of $67.62. Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $10.2 billion and is part of the drugs industry. Shares are up 0.2% year-to-date as of the close of trading on Friday. Currently there are 9 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 6 rate it a hold. TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Endo International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.